Proefschrift

De Angelis, G., Rittenhouse, H., Mikolajczyk, S., Shamel, B., and Semjonow, A. (2007). Twenty years of PSA: from prostate antigen to tumor marker. Reviews in Urology , 9(3):113–123. 5 De Bono, J., Logothetis, C., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K., Jones, R., Goodman Jr, O., and Saad, F. (2011). Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine , 364(21):1995–2005. 7, 49, 90 De Bono, J., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. The Lancet , 376(9747):1147–1154. 49 Denmeade, S. and Isaacs, J. (2002). A history of prostate cancer treatment. Nature Reviews Cancer , 2:389–396. 4 Denmeade, S., Sokoll, L., Dalrymple, S., Rosen, D., Gady, A., Bruzek, D., Ricklis, R., and Isaacs, J. (2003). Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. The Prostate , 54(4):249–257. 112 Dhawan, A., Nichol, D., Kinose, F., Abazeed, M., Marusyk, A., Haura, E., and Scott, J. (2017). Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer. Scientific Reports , 7(1):1–9. 97 Di Gregorio, A., Bowling, S., and Rodriguez, T. (2016). Cell competition and its role in the regulation of cell fitness from development to cancer. Developmental Cel l , 38(6):621–634. 76 Di Meo, A., Bartlett, J., Cheng, Y., Pasic, M., and Yousef, G. (2017). Liquid biopsy: a step forward towards precision medicine in urologic malignancies. Molecular cancer , 16(1):1–14. 76 Diaz Jr, L., Williams, R., Wu, J., Kinde, I., Hecht, R., Berlin, J., Allen, B., Bozic, I., Reiter, J., Nowak, M., et al. (2012). The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature , 486(7404):537–540. 8 Dingli, D., Chalub, F., Santos, F., Van Segbroeck, S., and Pacheco, J. (2009a). Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells. British Journal of Cancer , 101(7):1130–1136. 13, 27, 81 Dingli, D., Offord, C., Myers, R., Peng, K., Carr, T., Josic, K., Russell, S. J., and Bajzer, Z. (2009b). Dynamics of multiple myeloma tumor therapy with a recombinant measles virus. Cancer Gene Therapy , 16(12):873–882. 82 170